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MaOBJECTIVES The U.K. Transcatheter Aortic Valve Implantation Registry reported 30-day and 1-year mortality rates of
7.1% and 21.4%, respectively, for patients who underwent transcatheter aortic valve replacement (TAVR) in the United
Kingdom between 2007 and 2009. The study aim was to report long-term outcomes in this same cohort of patients.
BACKGROUND There are few data on outcomes beyond 3 years after TAVR in any notable number of patients.
METHODS Data from all TAVR procedures performed in the United Kingdom between January 2007 and December
2009 were prospectively collected. All-cause mortality status was reported in March 2014. Mortality tracking was
achieved in 97.7% patients.
RESULTS The minimal time from replacement to census was 4.1 years, and the maximal time was 7.0 years. The 3- and
5-year survival rates were 61.2% and 45.5%, respectively. Independent predictors of 3-year mortality were renal
dysfunction (hazard ratio [HR]: 1.65), atrial ﬁbrillation (HR: 1.36), logistic European System for Cardiac Operative Risk
Evaluation (EuroSCORE) $18.5 (HR: 1.33), respiratory dysfunction (HR: 1.28), and ventricular dysfunction (left ventricular
ejection fraction <30%) (HR: 1.53). Coronary artery disease (HR: 1.28) and age (HR: 1.03) were additional independent
predictors of mortality at 5 years. Stroke within 30 days of TAVR was the only independent procedural predictor of
mortality at 3 and 5 years (HR: 2.17 at 3 years). Device type, access route, and paravalvular leak did not independently
predict long-term outcome.
CONCLUSIONS In the large U.K. Transcatheter Aortic Valve Implantation Registry, long-term outcomes after
TAVR are favorable with 3- and 5-year survival rates of 61.2% and 45.5%, respectively. Long-term survival after TAVR
is largely determined by intrinsic patient factors. Other than stroke, procedural variables, including paravalvular aortic
leak, did not appear to be independent predictors of long-term survival. (J Am Coll Cardiol Intv 2015;8:645–53)
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ABBR EV I A T I ON S
AND ACRONYMS
EuroSCORE = European
System for Cardiac Operative
Risk Evaluation
HR = hazard ratio
LVEF = left ventricular
ejection fraction
TAVR = transcatheter
aortic valve replacement
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646S ymptomatic severe aortic stenosiscarries a poor prognosis (1,2). In thepast decade, transcatheter aortic valve
replacement (TAVR) has become an alterna-
tive treatment strategy to surgical aortic
valve replacement in high-risk patients
and is superior to conservative management
in inoperable patients (3). Randomized, con-
trolled trials and registry data have estab-
lished the safety and efﬁcacy of TAVR, andprocedural, 30-day, and 1-year outcomes after TAVR
have been well documented (4–7). The outcomes up
to 2 or 3 years have been reported (8–17). However,
longer term clinical outcomes beyond 3 years in any
notable number of patients are less frequently
described (18–20). The U.K. Transcatheter Aortic
Valve Implantation (U.K.-TAVI) Registry was set up
in 2007 as a national program to coordinate and
monitor the practice and dissemination of TAVR in
the United Kingdom and has captured every TAVR
performed in the United Kingdom since the beginning
of 2007. Initial data from the U.K.-TAVI Registry re-
ported 30-day, 1-year, and 2-year survival rates after
TAVR as 92.9%, 78.6%, and 73.7%, respectively, in
870 patients who underwent TAVR between January
1, 2007 and December 31, 2009 (21). The aim of the
current study was to report late clinical outcomes
and assess predictors of late mortality using data
from the U.K.-TAVI registry in this same initial cohort
of patients.SEE PAGE 654METHODS
The process of patient selection for TAVR was previ-
ously described in detail (19). Demographic data, risk
factors, and outcome measures of all patients who
underwent TAVR at a total of 25 centers in England and
Wales between January 1, 2007 and December 31, 2009
were collected and submitted to the National Institute
for Cardiovascular Outcomes Research (22), a web-
based system for data entry, encryption, and trans-
fer. This database formed the basis of the U.K.-TAVI
Registry (21). All ﬁelds were examined for missing
data or extreme values, and invalid data or values
indicating “unknown” were excluded from analysis.
Post-TAVR, aortic regurgitation (AR) was assessed
visually according to standard angiographic criteria at
the termination of the TAVR procedure (21). Mortality
tracking was undertaken by the National Health
Service Central Register using unique patient identi-
ﬁers. Survival status for the whole cohort was deter-
mined as of March 1, 2014. The study was performed
in compliance with current U.K. Data Protectionand Information Governance legislation. All patients
provided signed, informed consent.
STATISTICS. Categorical data were presented as per-
cents, and comparison between groups done using
the chi-square or Fisher exact test. Numerical data
were presented as mean  SD, and comparisons were
performed with the 2-sample Student t test or the
2-sample Wilcoxon rank sum (Mann-Whitney) test.
Time-to-event data analysis was performed using the
Cox proportional hazards model. Kaplan-Meier sur-
vival curves were drawn to assess differences between
groups for the time to an event data. For the Coxmodel,
univariate analysis of each of the possible predictors of
the outcome were tested, and only those variables that
were signiﬁcant at p < 0.05 were included in a multi-
variate model to determine the independent pre-
dictors of the outcome variables. The hazard ratio was
presented as mean and 95% conﬁdence interval. The
analysis was performed using Stata statistical software
version 10.1 (StataCorp, College Station, Texas).
RESULTS
Data for 877 valve implantations in 870 patients were
submitted to National Institute for Cardiovascular
Outcomes Research. A second TAVR was performed as
a valve-in-valve procedure after the original TAVR in 7
patients. The second procedure was censored, so that
the registry contained 870 patients. Completeness of
valid data was 99.6% for demographic data, 96.4% for
risk factors, 97.4% for procedural variables, and 98.5%
for in-hospital outcomes. All-cause mortality tracking
was performed on March 1, 2014 and was achieved in
850 patients (97.7%); an update of mortality tracking
in Scotland was not available. Thus, 850 patients
provide the basis of the survival analysis for this
study. The minimal time from TAVR to census was
4.1 years, and the maximal follow-up was 7.0 years.
BASELINE CHARACTERISTICS. Baseline demographic
data and risk factors are shown in Table 1. Signiﬁcant
concomitant coronary artery disease was deﬁned
as $50% stenosis affecting more than 1 major
epicardial coronary artery, and signiﬁcant renal
impairment was deﬁned as serum creatinine greater
than 200 mg/mmol. The median EuroSCORE (Euro-
pean System for Cardiac Operative Risk Evaluation)
was 18.5. A Medtronic CoreValve (Medtronic, Minne-
apolis, Minnesota) was deployed in 52.5% patients;
the remainder received an Edwards SAPIEN valve
(Edwards Lifesciences Corp., Irvine, California). The
access route was transfemoral in 68.4%.
PERIPROCEDURAL AND POST-PROCEDURAL OUTCOMES.
Peri- and post-procedural outcomes in this cohort
FIGURE 1 Kaplan-Meier Survival Curve for the U.K.
Transcatheter Aortic Valve Implantation Registry Cohort
Undergoing TAVR Between January 1, 2007 and December 31, 2009,
Censored January 3, 2014
A total of 550 patients were alive and at risk more than 3 years
after TAVR and 158 patients were alive and at risk more than 5
years after TAVR. The 3- and 5-year actuarial survival rates were
was 61.2% and 45.5%, respectively. TAVR ¼ transcatheter aortic
valve replacement.
TABLE 1 Baseline Demographics and TAVR Procedure (N ¼ 850)
Age, yrs 82  7
Male 442/850 (52.0)
Coronary artery disease 381/808 (47.2)
Previous cardiac surgery 248/833 (30.4)
Peripheral vascular disease 238/812 (29.8)
COPD 232/814 (28.5)
Atrial ﬁbrillation 202/846 (23.9)
Diabetes 193/841 (22.9)
Creatinine >200 mg/mmol 54/833 (6.5)
NYHA functional class I/II 197/846 (23.3)
NYHA functional class III/IV 649/846 (76.7)
LVEF $50% 549/845 (65.0)
LVEF 30%–49% 223/845 (26.4)
LVEF <30% 73/845 (8.6)
Aortic valve peak gradient, mm Hg 81  27
CoreValve* 442/843 (52.5)
SAPIEN valve† 401/846 (47.5)
Transfemoral route 581/850 (68.4)
Nontransfemoral route 269/850 (31.6)
Values are mean  SD or n (%). *Medtronic, Minneapolis, Minnesota. †Edwards
Lifesciences, Irvine, California.
COPD ¼ chronic obstructive pulmonary disease; LVEF ¼ left ventricular ejection
fraction; NYHA ¼ New York Heart Association; TAVR ¼ transcatheter aortic valve
replacement.
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647have been described in detail (21). In brief, procedural
success was achieved in 97.2% cases; the incidence of
stroke within 30 days, myocardial infarction, need for
new permanent pacing, and major vascular compli-
cations was 4.1%, 1.3%, 16.3%, and 8.4%, respec-
tively. Some degree of aortic paravalvular leak
(angiographic grade 1 or higher) occurred in 61% of
patients, with moderate to severe paravalvular leak
reported in 13.6%.
LONG-TERM MORTALITY. The Kaplan-Meier survival
curve for the whole population is shown in Figure 1. A
total of 515 patients were alive and at risk more than
3 years after TAVR, and 158 patients were alive and at
risk more than 5 years after TAVR. The 3- and 5-year
actuarial survival rates were 61.2% and 45.5%,
respectively.
PREDICTORS OF LONG-TERM MORTALITY. Base l ine
demographics . Demographic predictors of mortality
are presented in Tables 2 and 3. Independent pre-
dictors of mortality at 3 years were renal dysfunction,
atrial ﬁbrillation, chronic obstructive pulmonary dis-
ease, and logistic EuroSCORE $18.5. The baseline
left ventricular ejection fraction (LVEF) (<49%) was
an independent predictor of mortality at 3 years and
a predictor of mortality at 5 years when the LVEF
was <30%. At 5 years, renal dysfunction, atrial ﬁbril-
lation, chronic obstructive pulmonary disease, and
logistic EuroSCORE $18.5 again were independentpredictors of mortality, with the addition of coronary
artery disease and age (Figure 2). Sex, diabetes, previ-
ous cardiac surgery, peripheral vascular disease, New
York Heart Association functional class, and peak
aortic gradient were not independent predictors of
long-term mortality at either 3 or 5 years.
TAVR procedura l pred i ctors . The only indepen-
dent predictor of mortality at 3 and 5 years was
periprocedural stroke (Tables 4 and 5, Figure 3). There
was no signiﬁcant difference in mortality between
device type or access route, and neither was an
independent predictor of survival at either 3 or 5
years. The presence of moderate to severe para-
valvular leak (Figure 3), vascular complications, and
the need for permanent pacing were also not inde-
pendent predictors of long-term outcome.
DISCUSSION
Recent studies investigating long-term outcome up to
3 years after TAVR have reported survival rates of
between 62% and 74% at 2 years and between 56%
and 61% at 3 years (8–10,12,13,15,16,23). Most of these
studies, however, come from single centers, with
either limited patient numbers or a bias toward a
particular access route or device. In contrast, the
U.K.-TAVI Registry represents a ‘real-world’ experi-
ence. In the current study, we report the long-term
TABLE 2 Baseline Demographics: Predictors of Mortality at 3-Year Follow-Up
Alive
(n ¼ 520)
Dead
(n ¼ 330)
Univariate Model,
HR (95% CI) p Value
Multivariate Model,
HR (95% CI) p Value
Age, yrs 81  7 83  7 1.02 (1.00–1.03) 0.056 1.02 (1.00–1.04) 0.016
Male 259/520 (49.8) 183/330 (55.5) 1.18 (0.95–1.47) 0.130
Creatinine >200 mg/mmol 21/507 (4.1) 33/326 (10.1) 1.92 (1.34–2.76) <0.0001 1.86 (1.26–2.75) 0.002
Atrial ﬁbrillation 108/517 (20.9) 94/329 (28.6) 1.35 (1.07–1.72) 0.012 1.36 (1.05–1.76) 0.018
EuroSCORE $18.5 234/520 (45.0) 190/330 (57.8) 1.49 (1.19–1.85) <0.0001 1.24 (0.96–1.60) 0.099
COPD 126/499 (25.2) 106/315 (33.7) 1.37 (1.08–1.73) 0.009 1.34 (1.04–1.72) 0.024
LVEF
>50% 364/517 (70.4) 185/328 (56.4) 1.00 1.00
30%–49% 115/517 (22.2) 108/328 (32.9) 1.65 (1.30–2.09) <0.001 1.35 (1.02–1.77) 0.036
<30% 38/517 (7.4) 35/328 (10.7) 1.66 (1.15–2.38) 0.006 1.72 (1.16–2.54) 0.007
Diabetes 105/511 (20.6) 88/330 (26.7) 1.27 (0.99–1.62) 0.056
Coronary artery disease 225/498 (45.2) 156/310 (50.3) 1.19 (0.95–1.49) 0.123
Previous cardiac surgery 156/507 (30.8) 92/326 (28.2) 0.92 (0.72–1.17) 0.49
Peripheral vascular disease 137/493 (27.8) 101/319 (31.7) 1.17 (0.93–1.49) 0.18
NYHA functional class
I/II 129/517 (24.9) 68/329 (20.7) 1.00
III/IV 388/517 (75.1) 261/329 (79.3) 1.21 (0.93–1.58) 0.16
Aortic peak gradient, mm Hg 81  27 80  28 0.999 (0.995–1.003) 0.57
Values are mean  SD or n (%), unless otherwise indicated.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; other abbreviations as in Table 1.
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648outcome of patients with severe symptomatic aortic
stenosis who underwent TAVR in the United
Kingdom between January 2007 and December 2009,
regardless of access route or device. These data from
the U.K.-TAVI Registry reﬂect the largest series of
consecutive cases reported to date of long-term
outcome after TAVR, with a minimal follow-upTABLE 3 Baseline Demographics: Predictors of Mortality at 5-Year F
Alive
(n ¼ 387)
Dead
(n ¼ 463)
Age, yrs 81  8 83  6
Male 192/387 (49.4) 251/463 (54.2)
Creatinine >200 mg/mmol 16/377 (4.2) 39/442 (8.8)
COPD 89/373 (23.9) 143/441 (32.4)
Atrial ﬁbrillation 79/385 (20.5) 123/461 (26.7)
Coronary artery disease 160/372 (43.0) 221/436 (50.1)
EuroSCORE $18.5 164/387 (42.4%) 260/463 (56.2)
LVEF
>50% 267/386 (69.2) 282/459 (61.4)
30%–49% 88/386 (22.8) 135/459 (29.4)
<30% 31/386 (8.0) 42/445 (9.2)
Diabetes 77/381 (20.2) 116/460 (25.2)
Peripheral vascular disease 101/368 (27.5) 137/444 (30.9)
Previous cardiac surgery 119/379 (31.4) 129/454 (28.4)
NYHA functional class
I/II 97/385 (25.2) 100/461 (21.7)
III/IV 298/385 (74.8) 361/461 (78.3)
Aortic peak gradient, mm Hg 81  27 81  28
Values are mean  SD or n (%), unless otherwise indicated.
Abbreviations as in Tables 1 and 2.period of more than 4 years and a maximal follow-
up of just more than 7 years.
Pr inc ipa l ﬁndings . The U.K.-TAVI Registry study
demonstrated favorable long-term outcomes after
TAVR. From a cohort of 850 patients with a mean age
of 82 years at the time of the TAVR procedure, a large
number of patients (n ¼ 515) were alive and at riskollow-Up
Univariate Model,
HR (95% CI) p Value
Multivariate Model,
HR (95% CI) p Value
1.02 (1.01–1.04) 0.001 1.03 (1.01–1.05) <0.001
1.15 (0.96–1.38) 0.132
1.67 (1.19–2.32) 0.003 1.60 (1.11–2.32) 0.013
1.33 (1.09–1.63) 0.005 1.40 (1.12–1.74) 0.003
1.30 (1.06–1.60) 0.013 1.30 (1.04–1.63) 0.020
1.25 (1.03–1.50) 0.021 1.35 (1.10–1.65) 0.004
1.47 (1.23–1.77) <0.0001 1.32 (1.07–1.62) 0.009
1.00 1.00
1.38 (1.13–1.70) 0.002 1.17 (0.93–1.49) 0.182
1.36 (0.98–1.88) 0.062 1.36 (0.97–1.92) 0.073
1.22 (0.99–1.51) 0.063 1.22 (0.97–1.54) 0.096
1.15 (0.94–1.40) 0.181
0.92 (0.75–1.13) 0.409
1.18 (0.94–1.47) 0.149
0.999 (0.996–1.002) 0.715
FIGURE 2 Demographic Predictors of 5-Year Survival After TAVR
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Renal impairment, respiratory disease (chronic obstructive pulmonary disease), ventricular dysfunction, and atrial ﬁbrillation were independent
predictors of mortality at 3 years. All remained independent predictors of mortality at 5 years. Age and coronary artery disease emerged as
independent predictors of mortality for the ﬁrst time. AF ¼ atrial ﬁbrillation; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive
pulmonary disease.
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649more than 3 years after TAVR, and the 3-year survival
rate was 61.2%. This is similar to results from several
recent single-center studies (10,15,16,23) and is com-
parable to the 66.1% 2-year survival rate in theTABLE 4 Device/Access/Procedural Complications as Predictors of M
Alive
(n ¼ 520)
Dead
(n ¼ 330)
Device type
CoreValve* 283/519 (54.5) 159/324 (49.1
SAPIEN† 236/519 (45.5) 165/324 (50.9
Route
Transfemoral 369/520 (70.9) 212/330 (64.2
Nontransfemoral 151/520 (29.1) 118/330 (35.8
Procedural complications
Stroke 13/520 (2.5) 21/324 (6.5)
Major vascular complication 28/520 (5.4) 26/329 (7.9)
Moderate/severe paravalvular leak 63/512 (12.3) 47/319 (14.7
Permanent pacemaker 85/519 (16.4) 53/328 (16.2
Values are n (%) unless otherwise indicated. *Medtronic, Minneapolis, Minnesota. †Edw
Abbreviations as in Table 2.PARTNER A (Placement of Aortic Transcatheter
Valves) trial (11) and better than the 3-year survival
rate in the PARTNER B trial (45.9%) (18), although
we note that the cohort of patients reported in theortality at 3-Year Follow-up
Univariate Model,
HR (95% CI) p Value
Multivariate Model,
HR (95% CI) p Value
) 0.84 (0.67–1.04) 0.11
) 1.00
) 0.76 (0.61–0.95) 0.018 0.81 (0.64–1.02) 0.077
) 1.00 1.00
2.33 (1.50–3.63) <0.0001 2.32 (1.47–3.65) <0.001
1.47 (0.98–2.19) 0.059
) 1.22 (0.90–1.67) 0.20
) 0.97 (0.73–1.31) 0.86
ards Lifesciences, Irvine, California.
TABLE 5 Device/Access/Procedural Complications as Predictors of Mortality at 5-Year Follow-up
Alive
(n ¼ 387)
Dead
(n ¼ 463)
Univariate Model
HR (95% CI) p Value
Multivariate Model
HR (95% CI) p Value
Device type
CoreValve* 212/386 (54.9) 230/467 (50.33) 0.86 (0.71–1.03) 0.103
SAPIEN valve† 174/386 (45.1) 227/457 (49.7) 1.00
Route
Transfemoral 281/387 (72.6) 300/463 (64.8) 0.76 (0.62–0.91) 0.004 0.88 (0.71–1.09) 0.241
Nontransfemoral 106/387 (27.4) 163/463 (35.2) 1.00 1.00
Procedural complications
Cerebrovascular accident 10/387 (2.6) 24/457 (5.3) 1.93 (1.28–2.91) 0.002 1.84 (1.19–2.82) 0.006
Moderate/severe paravalvular leak 45/383 (11.8) 65/448 (14.5) 1.22 (0.92–1.58) 0.145 1.25 (0.95–1.66) 0.115
Major vascular complications 24/387 (6.2) 30/462 (6.5) 1.21 (0.83–1.75) 0.319
Permanent pacemaker 62/387 (16.0) 76/460 (16.5) 0.99 (0.77–1.26) 0.924
Values are n (%) unless otherwise indicated. *Medtronic, St. Paul, Minnesota. †Edwards Lifesciences, Irvine, California.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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PARTNER A– and PARTNER B–type patients (i.e.,
encompassing both high and extreme risk). Very few
studies have reported 5-year survival rate after TAVR,
and those that have report many fewer patients alive
and at risk at 5 years compared with this study
(18–20). In the U.K.-TAVI Registry, a sizable number
of patients (n ¼ 158) were still alive and at risk more
than 5 years after TAVR. The actuarial survival rate
was 45.5%. Previous studies report 5-year survival
rates between 35% and 41% (18–20).
In the initial U.K.-TAVI Registry report (21), 1-year
predictors of mortality were left ventricular impair-
ment (LVEF #30%), chronic obstructive pulmonary
disease, and the presence of moderate to severe par-
avalvular aortic regurgitation (22). In essentially the
same cohort of patients in the current study, long-
term mortality was dominated by intrinsic patient
factors (signiﬁcant renal dysfunction, atrial ﬁbrilla-
tion, respiratory disease, impaired left ventricular
function, and logistic EuroSCORE) (18,19,23–29). The
only procedural variable that was an independent
predictor of long-term mortality was post-procedural
stroke, which was associated with a more than 2-fold
risk of death at 3 years with a similar ﬁnding at 5
years. At 5 years, advancing age emerged as an addi-
tional independent predictor of mortality, as did cor-
onary artery disease. Because coronary artery disease
has not previously been shown to be a predictor of
early and mid-term outcome after TAVR (21,30,31), we
speculate that the progression of coronary artery dis-
ease with longer follow-up after TAVR may be clini-
cally important. Sex (32) and previous cardiac surgery
(33) did not predict long-term survival. Left ventricu-
lar function (LVEF 30% to 49% and <30%) were both
independent predictors of mortality at 3 and 5 years,
but only LVEF predicted mortality at 5 yearswhen <30%. This result is difﬁcult to explain; we
postulate that it may have been as a result of a rela-
tively small but statistically important number of
missing data in patients with an LVEF of 30% to 49%
who died after 5 years compared with other groups.
As reported, stroke within 30 days of TAVR was the
only independent predictor of long-term mortality.
There was no statistically signiﬁcant difference in
mortality rates at either 3 or 5 years between patients
treated with the SAPIEN or CoreValve devices. We
acknowledge that in the cohort studied, more than
one-half of the SAPIEN procedures were performed
via the transapical approach, whereas more than 90%
of CoreValve procedures were performed trans-
femorally (21), and so the access route may have been
a confounding factor in this analysis. However, we
found no difference in mortality rates when trans-
femoral access was compared with nontransfemoral
access. Similar ﬁndings were reported recently in the
PRAGMATIC (Pooled Rotterdam-Milan-Toulouse In
Collaboration) and CHOICE (A Comparison of Trans-
catheter Heart Valves in High Risk Patients With
Severe Aortic Stenosis: Medtronic CoreValve Versus
Edwards Sapien XT) studies, which found no signiﬁ-
cant between-group differences in procedural, 30-
day, and 1-year mortality rates or in symptom
improvement between device types (34,35). Perhaps
the most controversial was the ﬁnding that more than
moderate paravalvular leak was not an independent
predictor of long-term outcome in the U.K.-TAVI
Registry (36). Moderate to severe paravalvular aortic
regurgitation has previously been consistently shown
to be associated with reduced early survival after
TAVR (11,13,37–39), and indeed, the U.K.-TAVI Reg-
istry report in 2011 was one of the ﬁrst to demonstrate
that paravalvular aortic regurgitation was associated
with increased mortality at 1 year (21). However, in
FIGURE 3 Procedural Predictors of 5-Year Survival After TAVR
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Stroke-associated with TAVR had a highly signiﬁcant effect on long-term survival. There was a trend toward reduced mortality with a Medtronic
CoreValve compared with an Edwards SAPIEN device via a transfemoral approach compared with a nontransfemoral approach and with the
absence of moderate to severe paravalvular leak, but these did not reach statistical signiﬁcance. AR ¼ aortic regurgitation; CVA ¼ cerebro-
vascular accident; mod/sev ¼ moderate to severe; PVL ¼ paravalvular leak; TAVR ¼ transcatheter aortic valve replacement.
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651the same cohort of patients in the current study, there
was only a nonsigniﬁcant trend toward reduced
survival in patients with moderate to severe para-
valvular leak 5 years after TAVR. Potential explana-
tions include our use of all-cause mortality rather
than cardiovascular mortality as an endpoint. Several
studies have shown limited predictive power of par-
avalvular leak with all-cause mortality, and in the
recent PARTNER B trial 5-year follow-up report, only
cardiovascular mortality (not all-cause mortality) was
inﬂuenced by moderate to severe paravalvular leak
(17). Moreover, in the U.K.-TAVI Registry, angio-
graphic paravalvular leak severity was self-reported
without core lab adjudication; thus, interobserver
variability in the estimation of regurgitation severity
might explain the lack of independent predictive
value of paravalvular leak on long-term mortality.
However, the methodology described was robust
enough to show a difference at 1 year. Because mod-
erate to severe paravalvular leak proved to be asigniﬁcant predictor of mortality at 1 year in the
U.K.-TAVI Registry (19), the reduced predictive trends
at 3 and 5 years in the same cohort of patients might
be related to the high incidence of overall mortality
(55%) for nonrelated causes. Alternatively, intrinsic
patient comorbidities may actually overwhelm the
deleterious effects of paravalvular leak in the long
term, or the presence of paravalvular leak may be
itself a surrogate for patients with signiﬁcant comor-
bidities (40). Continued advances in imaging to size
the aortic annulus with greater accuracy, along with
improvements in device function, should in any case
reduce the incidence of paravalvular leak after TAVR,
and the uncertainty over the long-term effect of
paravalvular leak may become less important than
reported after TAVR when the procedure was in its
relative infancy.
STUDY LIMITATIONS. Like all registries, ours is only
as credible as the quality of the data within it. Data
PERSPECTIVES
The U.K.-Transcatheter Aortic Valve Implantation
(TAVI) Registry previously reported a 30-day mortal-
ity rate of 7.1% and a 1-year mortality rate of 21.4%
in patients undergoing transcatheter aortic valve
replacement between January 2007 and December
2009. In the same cohort, we report 3- and 5-year
mortality of survival rates of 38.8% and 54.5%,
respectively. Long-term survival after transcatheter
aortic valve replacement was determined by intrinsic
patient factors (age, baseline renal dysfunction,
respiratory dysfunction, ventricular dysfunction, cor-
onary artery disease, and atrial ﬁbrillation). Peripro-
cedural stroke was the only independent procedural
predictor of mortality. Device type, access route, and
paravalvular leak did not independently predict long-
term outcome.
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652completeness in this registry was good, but although
data on the numbers of procedures and survival
outcome is believed to be extremely robust, data
concerning morbidity and complications are likely
less so. Although internal consistency checks were
applied, these data are self-reported and have not
been systematically validated or independently
adjudicated. Through the Ofﬁce of National Statistics,
the U.K.-TAVI Registry reports the date of death, not
cause of death, and therefore our study was only able
to report all-cause mortality, not cardiovascular
mortality. Determining predictors of late mortality in
a highly comorbid group of patients in whom
noncardiac death may have been frequent and in
whom even cardiac death may have been unrelated to
valve-related complications is thus a limitation of the
study, and many “true” predictors of mortality may
have been overshadowed by the overall high rates of
mortality due to other causes. Our results may thus
have favored baseline patient demographics (such as
age and coronary and renal disease) as positive pre-
dictors of mortality because these are generally
associated with late mortality. Procedural factors
(which would not normally be associated with late
mortality) may have therefore been less discriminant,
remaining only as trends without statistical signiﬁ-
cance. Moreover, we were unable to provide risk ad-
justments or propensity-matched cohorts to support
our results. Speciﬁcally with respect to paravalvular
leak, although the numbers of patients at risk are
larger than in other studies, the actual numbers are
still relatively small, and, thus, there may be a chance
of a type II error in the ﬁnding that paravalvular aortic
regurgitation did not inﬂuence long-term mortality.
We will be able to address this concern in future
follow-up studies from the Registry.CONCLUSIONS
Although procedural factors are important predictors
of early mortality, this study suggests that the
dominant predictors of long-term mortality after
TAVR are intrinsic patient factors. At 5 years, age and
the presence of concomitant coronary artery disease
emerge for the ﬁrst time as independent predictors of
mortality. The only procedural variable that was an
independent predictor of long-term mortality was
post-procedural stroke.
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